Skip to main content
AAN.com
Articles
May 7, 2007

Rate, degree, and predictors of recovery from disability following ischemic stroke

May 8, 2007 issue
68 (19) 1583-1587

Abstract

Objective: To determine the rate, degree, and predictors of recovery from disabling ischemic stroke.
Methods: Patients with ischemic stroke enrolled in the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study underwent long-term prospective assessment of their modified Rankin Scale (mRS) score. Disability (functionally dependent state) was defined as mRS ≥ 3, and recovery (functionally independent state) was defined as mRS < 3. The timing and the independent predictors of recovery were determined using a Cox proportional hazards multiple regression analysis.
Results: Of 7,599 patients enrolled with ischemic stroke or TIA, 1,662 (21.8%) were disabled (mRS ≥ 3) at baseline (median of 14 [0 to 96] days after stroke onset). Disability was moderate (mRS 3) in 931 (56%) patients, severe (mRS 4) in 691 (42%), and very severe (mRS 5) in 40 (2%). By 18 months, 877 (52.8%, 95% CI 50% to 55%) patients had recovered, 589 (63%, 60% to 66%) with moderate disability, 281 (41%, 37% to 44%) with severe disability, and 7 (17%, 7 to 33%) with very severe disability. Median time to recovery was 3 months for patients with moderate disability and 18 months for severe disability; 82.5% of severely disabled patients remained so at 18 months. Predictors of recovery were moderate disability (mRS 3) at baseline compared with severe (mRS 4: hazard ratio [HR] 2.13, 1.86 to 2.44) or very severe disabling stroke (HR 5.88, 2.86 to 12.5); younger women (aged <65 years, compared with ≥75 years; HR 1.85, 1.47 to 2.33); decreasing time (days) between the qualifying event and the baseline assessment (HR 1.01, 1.01 to 1.02); and the absence of previous ischemic stroke (HR 1.61, 1.35 to 1.92), concurrent peripheral artery disease (HR 1.61, 1.23 to 2.13), or diabetes (HR 1.30, 1.10 to 1.54).
Conclusions: Half of patients with disabling ischemic stroke recovered within 18 months, and recovery was greatest within 6 months. Significant predictors of recovery included the severity of the index stroke and no history of ischemic stroke, peripheral artery disease, or diabetes.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.doc)

REFERENCES

1.
Dombovy ML, Basford JR, Whisnant JP, Bergstralh EJ. Disability and use of rehabilitation services following stroke in Rochester, Minnesota, 1975-1979. Stroke 1987;18:830–836.
2.
Wilkinson PR, Wolfe CD, Warburton FG, et al. A long-term follow-up of stroke patients. Stroke 1997;28:507–512.
3.
Kadojic D, Misevic S, Bradvica I, Barac B, Janculjak D, Kadojic M. Outcome of ischemic stroke: a five-year follow-up study. Acta Clinica Croatica 2000;39:277–280.
4.
Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:731–735.
5.
Weimar C, Kurth T, Kraywinkel K, et al. Assessment of functioning and disability after ischemic stroke. Stroke 2002;33:2053–2059.
6.
Lai SM, Duncan PW. Stroke recovery profile and the Modified Rankin assessment. Neuroepidemiology 2001;20:26–30.
7.
Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702–710.
8.
Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002;33:1034–1040.
9.
Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003;34:122–126.
10.
Diener HC, Bogousslavsky J, Brass LM, et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc Dis 2004;17:253–261.
11.
Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
12.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–1054.
13.
Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis Scott Med J 1957;2:200–215.
14.
Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000;39:835–841.
15.
Kimura K, Kazui S, Minematsu K, Yamaguchi T. Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan: a hospital-based prospective registration study. Cerebrovasc Dis 2004;18:47–56.
16.
Spieler JF, Lanoe JL, Amarenco P. Costs of stroke care according to handicap levels and stroke subtypes. Cerebrovasc Dis 2004;17:134–142.

Information & Authors

Information

Published In

Neurology®
Volume 68Number 19May 8, 2007
Pages: 1583-1587
PubMed: 17485645

Publication History

Published online: May 7, 2007
Published in print: May 8, 2007

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

G. J. Hankey, MD, FRCP, FRACP
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.
J. Spiesser, MSc
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.
Z. Hakimi, PharmD
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.
G. Bego, MSc
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.
P. Carita, PhD
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.
S. Gabriel, MD
From the Stroke Unit (G.J.H.), Royal Perth Hospital, Perth, Australia; the School of Medicine and Pharmacology (G.J.H.), University of Western Australia, Crawley, Australia; and Sanofi-Aventis Recherche & Développement (J.S., Z.H., G.B., P.C., S.G.), Bagneux, France.

Notes

Address correspondence and reprint requests to Dr. Graeme J. Hankey, Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington St., Perth, Australia 6001 [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Molecular Targeting of Ischemic Stroke: The Promise of Naïve and Engineered Extracellular Vesicles, Pharmaceutics, 16, 12, (1492), (2024).https://doi.org/10.3390/pharmaceutics16121492
    Crossref
  2. Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives, PLOS ONE, 19, 2, (e0297939), (2024).https://doi.org/10.1371/journal.pone.0297939
    Crossref
  3. One‐Year Disability Trajectories and Long‐Term Cardiovascular Events, Recurrent Stroke, and Mortality After Ischemic Stroke, Journal of the American Heart Association, 13, 3, (2024).https://doi.org/10.1161/JAHA.123.030702
    Crossref
  4. What the National Coverage Determination for Carotid Artery Stenting Means for the Treatment of Patients with Carotid Artery Disease, Annals of Vascular Surgery, (2024).https://doi.org/10.1016/j.avsg.2024.09.037
    Crossref
  5. Post-Stroke Brain Health Monitoring and Optimization: A Narrative Review, Journal of Clinical Medicine, 12, 23, (7413), (2023).https://doi.org/10.3390/jcm12237413
    Crossref
  6. Measurement Property Evaluation of the Arabic Version of the Patient-Specific Functional Scale for Patients with Stroke, Healthcare, 11, 11, (1642), (2023).https://doi.org/10.3390/healthcare11111642
    Crossref
  7. Variability of the Modified Rankin Scale Score Between Day 90 and 1 Year After Ischemic Stroke, Neurology Clinical Practice, 11, 3, (e239-e244), (2023)./doi/10.1212/CPJ.0000000000000954
    Abstract
  8. EXERTION: a pilot trial on the effect of aerobic, smartwatch-controlled exercise on stroke recovery: effects on motor function, structural repair, cognition, mental well-being, and the immune system, Neurological Research and Practice, 5, 1, (2023).https://doi.org/10.1186/s42466-023-00244-w
    Crossref
  9. Determining the factors influencing the selection of post-acute care models by patients and their families: a qualitative content analysis, BMC Geriatrics, 23, 1, (2023).https://doi.org/10.1186/s12877-023-03889-z
    Crossref
  10. The efficacy of hybrid neuroprostheses in the rehabilitation of upper limb impairment after stroke, a narrative and systematic review with a meta‐analysis, Artificial Organs, 48, 3, (232-253), (2023).https://doi.org/10.1111/aor.14618
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share